<DOC>
	<DOCNO>NCT02442375</DOCNO>
	<brief_summary>The objective UPGRADE-RT trial investigate whether de-escalation elective radiation dose introduction intermediate dose-level treatment head neck cancer result le radiation sequela improve quality life treatment whilst recurrence rate electively irradiate lymph node compromise . A summary study protocol find : http : //rdcu.be/qgMv</brief_summary>
	<brief_title>Uniform FDG‐PET Guided Gradient Dose Prescription Reduce Late Radiation Toxicity</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>1 . Newly diagnose tumour classify stage T2‐4 N0‐2 locate larynx , oropharynx hypopharynx ( unknown primary oral cavity eligible ) 2 . Histopathological diagnosis invasive squamous cell carcinoma primary tumour 3 . Decision curative intent external beam radiotherapy elective treatment neck make multidisciplinary head‐and‐neck oncology team . The patient must expect complete treatment . 4 . Radiotherapy plan start within 6 week baseline image tumour assessment 5 . No distant metastasis ( M0 ) 6. WHO performance status 0‐2 7 . ≥ 18 year age 8 . Written inform consent 1 . Concomitant chemotherapy EGFR inhibitor tumour . 2 . Primary tumour oral cavity unknown primary tumour 3 . Prior current anticancer treatment head neck area ( e.g . radical attempt tumour reductive surgery , neo‐adjuvant concomitant chemotherapy , EGFR inhibitor radiotherapy ) , except endoscopic glottic laser micro surgery . 4 . Current participation interventional clinical study . 5 . Uncontrolled diabetes mellitus . 6 . Known suspected HIV infection . 7 . History previous malignancy within last 3 year , exception surgically cure carcinoma situ cervix , situ breast cancer , incidental finding stage T1a T1b prostate cancer , basal/squamous cell carcinoma skin . 8 . Any condition ( somatic , psychological , familial , sociological geographical ) render patient unable understand complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>accelerate radiotherapy</keyword>
	<keyword>dose reduction</keyword>
	<keyword>dose de-escalation</keyword>
	<keyword>elective lymph node</keyword>
	<keyword>FDG-PET</keyword>
</DOC>